Drug Trial Radar · NCT07306624
Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
62
Planned (sponsor's estimate)
Start
Jan 10, 2026
Primary completion
Aug 31, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- STCube, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Multicenter, Phase 2 Clinical Trial Based on an Adaptive Design to Evaluate the Safety and Efficacy of Nelmastobart in Combination with Docetaxel in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer Who Are Resistant or Intolerant to Platinum-based Chemotherapy and/or Immunotherapy
Conditions
- Non Small Cell Lung Cancer
Interventions
Nelmastobart and DocetaxelDrug
Nelmastobart 800mg and Docetaxel 75mg/m2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival by central reviewerTime frame: up to 3 years
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
The Catholic University of Korea St. Vincent's Hospital
Gyeonggi-do, South Korea · Recruiting
Kangbuk Samsung Hospital
Seoul, South Korea · Recruiting
Korea University Anam Hospital
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Seoul National University Bundang Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.